Investigational drugs for the treatment of dysmenorrhea

References

• Armour M, Parry K, Manohar N, et al. The prevalence and academic impact of dysmenorrhea in 21,573 young women: a systematic review and meta-analysis. J Womens Health (Larchmt). 2019 Aug;28(8):1161–1171. doi: 10.1089/jwh.2018.7615
   PubMed Web of Science ®Google Scholar
• International Association for the Study of Pain. Classification of Chronic Pain. Second Edition (Revised). Second. 2011 28. Sept 2020. https://www.iasp-pain.org/publications/free-ebooks/classification-of-chronic-pain-second-edition-revised/
   Google Scholar
• Iacovides S, Avidon I, Bentley A, et al. Reduced quality of life when experiencing menstrual pain in women with primary dysmenorrhea. Acta Obstet Gynecol Scand. 2014 Feb;93(2):213–217. doi: 10.1111/aogs.12287
   PubMed Web of Science ®Google Scholar
• Armour M, Sinclair J, Ng CHM, et al. Endometriosis and chronic pelvic pain have similar impact on women, but time to diagnosis is decreasing: an Australian survey. Sci Rep. 2020 Oct 1 10(1):16253. doi: 10.1038/s41598-020-73389-2
   PubMed Web of Science ®Google Scholar
• Simoens S, Dunselman G, Dirksen C, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012 May;27(5):1292–1299. doi: 10.1093/humrep/des073
   PubMed Web of Science ®Google Scholar
• Schoep ME, Adang EMM, Maas JWM, et al. Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women. BMJ Open. 2019 Jun 27 9(6):e026186. doi: 10.1136/bmjopen-2018-026186
   PubMed Web of Science ®Google Scholar
• Armour M, Ciccia D, Yazdani A, et al. Endometriosis research priorities in Australia. Aust N Z J Obstet Gynaecol. 2023 Aug;63(4):594–598. doi: 10.1111/ajo.13699
   PubMed Web of Science ®Google Scholar
• Holmes K, Curry C, Sherry FT, et al. Adolescent menstrual health literacy in low, middle and high-income countries: a narrative review. Int J Environ Res Public Health. 2021 Feb 25 18(5):2260. doi: 10.3390/ijerph18052260
   PubMed Web of Science ®Google Scholar
• Armour M, Hyman MS, Al-Dabbas M, et al. Menstrual health literacy and management strategies in young women in Australia: a national online survey of young women aged 13-25 years. J Pediatr Adolesc Gynecol. 2021 Apr;34(2):135–143. doi: 10.1016/j.jpag.2020.11.007
   PubMed Web of Science ®Google Scholar
• Sinclair J, Armour S, Akowuah JA, et al. Should I inhale?;Perceptions, barriers, and drivers for medicinal cannabis use amongst Australian women with primary dysmenorrhoea: a qualitative study. Int J Environ Res Public Health. 2022;19(3):1536. doi: 10.3390/ijerph19031536
   PubMed Web of Science ®Google Scholar
• Coco AS. Primary dysmenorrhea. Am Fam Physician. 1999 Aug;60(2):489–496.
   PubMed Web of Science ®Google Scholar
• Guimaraes I, Povoa AM. Primary dysmenorrhea: assessment and treatment. Rev Bras Ginecol Obstet. 2020 Aug;42(8):501–507.
   PubMedGoogle Scholar
• Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea.BMJ. 2006 May 13 332(7550):1134–1138. doi: 10.1136/bmj.332.7550.1134
   PubMedGoogle Scholar
• Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol. 2006 Aug;108(2):428–441. doi: 10.1097/01.AOG.0000230214.26638.0c
   PubMed Web of Science ®Google Scholar
• Morrow C, Naumburg EHD, Care P. Dysmenorrhea. Primary Care. 2009 Mar;36(1):19–32. vii
   PubMed Web of Science ®Google Scholar
• Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception. 2010 Mar;81(3):185–196.
   PubMed Web of Science ®Google Scholar
• Chan WY, Hill JC. Determination of menstrual prostaglandin levels in non-dysmenorrheic and dysmenorrheic subjects. Prostaglandins. 1978 Feb;15(2):365–375.
   PubMedGoogle Scholar
• Weissman AM, Hartz AJ, Hansen MD, et al. The natural history of primary dysmenorrhoea: a longitudinal study. BJOG. 2004 Apr;111(4):345–352. doi: 10.1111/j.1471-0528.2004.00090.x
   PubMed Web of Science ®Google Scholar
• Lundstrom V, Green K. Endogenous levels of prostaglandin F2 and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol. 1978;130(6):640–646.
   PubMed Web of Science ®Google Scholar
• Harel Z. Dysmenorrhea in adolescents and young adults: from pathophysiology to pharmacological treatments and management strategies. Expert Opin Pharmacother. 2008 Oct;9(15):2661–2672.
   PubMed Web of Science ®Google Scholar
• Wilhelmsson L, Lindblom B, Wikland M, et al. PGI 2 may play a role in the pathophysiology of dysmenorrhea. Acta Obstet Gynecol Scand Suppl. 1983;113(s113):69–70. doi: 10.3109/00016348309155201
   PubMedGoogle Scholar
• Buster JE. Dysmenorrhea and premenstrual syndrome. Hacker NF, Moore JG essentials of obstetrics and gynecology Philadelphia: WB Saunders. 1986;259–264.
   Google Scholar
• Howard F, Perry P, Carter J, et al. Pelvic pain diagnosis and management. Philadelphia: Lippincot Williams and Wilkins; 2000.
   Google Scholar
• Dmitrovic R. Transvaginal color Doppler study of uterine blood flow in primary dysmenorrhea. Acta Obstet Gynecol Scand. 2000 Dec;79(12):1112–1116.
   PubMed Web of Science ®Google Scholar
• Akerlund M. Vascularization of human endometrium. Uterine blood flow in healthy condition and in primary dysmenorrhoea.Ann N Y Acad Sci. 1994 Sep 30 734(1):47–56. doi: 10.1111/j.1749-6632.1994.tb21735.x
   PubMedGoogle Scholar
• Rees MC, DiMarzo V, Tippins JR, et al. Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. J Endocrinol. 1987 May;113(2):291–295. doi: 10.1677/joe.0.1130291
   PubMed Web of Science ®Google Scholar
• Nigam S, Benedetto C, Zonca M, et al. Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoids. 1991;4(3):137–141.
   PubMedGoogle Scholar
• Harel Z, Riggs S, Vaz R, et al. The use of the leukotriene receptor antagonist montelukast (Singulair) in the management of dysmenorrhea in adolescents. J Pediatr Adolesc Gynecol. 2004 Jun;17(3):183–186. doi: 10.1016/j.jpag.2004.03.037
   PubMedGoogle Scholar
• Chen YL, Shepherd C, Spinelli W, et al. Oxytocin and vasopressin constrict rat isolated uterine resistance arteries by activating vasopressin V1A receptors. Eur J Pharmacol. 1999 Jul 2 376(1–2):45–51. doi: 10.1016/S0014-2999(99)00351-9
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Garfield RE. Role of nitric oxide in implantation and menstruation. Hum Reprod. 2000 Aug;15(suppl 3):96–111.
   PubMedGoogle Scholar
• Dikensoy E, Balat O, Pence S, et al. Malondialdehyde, nitric oxide and adrenomedullin levels in patients with primary dysmenorrhea. J Obstet Gynaecol Res. 2008 Dec;34(6):1049–1053. doi: 10.1111/j.1447-0756.2008.00802.x
   PubMed Web of Science ®Google Scholar
• Sun MF, Huang HC, Lin SC, et al. Evaluation of nitric oxide and homocysteine levels in primary dysmenorrheal women in Taiwan. Life Sci. 2005 Mar 11 76(17):2005–2009. doi: 10.1016/j.lfs.2004.09.030
   PubMed Web of Science ®Google Scholar
• Ekstrom P, Akerlund M, Forsling M, et al. Stimulation of vasopressin release in women with primary dysmenorrhoea and after oral contraceptive treatment–effect on uterine contractility. Br J Obstet Gynaecol. 1992 Aug;99(8):680–684. doi: 10.1111/j.1471-0528.1992.tb13855.x
   PubMedGoogle Scholar
• Valentin L, Sladkevicius P, Kindahl H, et al. Effects of a vasopressin antagonist in women with dysmenorrhea. Gynecol Obstet Invest. 2000;50(3):170–177. doi: 10.1159/000010319
   PubMed Web of Science ®Google Scholar
• Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ. 2014 Mar 19 348:g1752. doi: 10.1136/bmj.g1752
   PubMedGoogle Scholar
• Zondervan KT, Becker CM, Koga K, et al. Endometriosis [Review]. Nat Rev Dis Primers. 2018 Jul 19 4(1):9. doi: 10.1038/s41572-018-0008-5
   PubMedGoogle Scholar
• Horne AW, Missmer SA. Pathophysiology, diagnosis, and management of endometriosis. BMJ. 2022 Nov 14;379:e070750. doi: 10.1136/bmj-2022-070750
   PubMedGoogle Scholar
• Saunders PTK, Horne AW. Endometriosis: etiology, pathobiology, and therapeutic prospects. Cell. 2021 May 27;184(11):2807–2824. doi: 10.1016/j.cell.2021.04.041
   PubMed Web of Science ®Google Scholar
• As-Sanie S, Harris RE, Napadow V, et al. Changes in regional gray matter volume in women with chronic pelvic pain: a voxel-based morphometry study. Pain. 2012 May;153(5):1006–1014. doi: 10.1016/j.pain.2012.01.032
   PubMed Web of Science ®Google Scholar
• Coxon L, Horne AW, Vincent K. Pathophysiology of endometriosis-associated pain: a review of pelvic and central nervous system mechanisms. Best Pract Res Clin Obstet Gynaecol. 2018 Aug;51:53–67.
   PubMed Web of Science ®Google Scholar
• Harel Z. Dysmenorrhea in adolescents and young adults: an update on pharmacological treatments and management strategies. Expert Opin Pharmacother. 2012 Oct;13(15):2157–2170.
   PubMed Web of Science ®Google Scholar
• Mardon AK, Leake HB, Szeto K, et al. Treatment recommendations for the management of persistent pelvic pain: a systematic review of international clinical practice guidelines. BJOG. 2022 Jul;129(8):1248–1260. doi: 10.1111/1471-0528.17064
   PubMed Web of Science ®Google Scholar
• Nie W, Xu P, Hao C, et al. Efficacy and safety of over-the-counter analgesics for primary dysmenorrhea: a network meta-analysis. Medicine (Baltimore). 2020 May;99(19):e19881. doi: 10.1097/MD.0000000000019881
   PubMed Web of Science ®Google Scholar
• Marjoribanks J, Ayeleke RO, Farquhar C, et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015 Jul 30 2015(7):CD001751. doi: 10.1002/14651858.CD001751.pub3
   PubMedGoogle Scholar
• Brown J, Crawford TJ, Allen C, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev. 2017 Jan 23;1(1):CD004753. doi: 10.1002/14651858.CD004753.pub4
   PubMedGoogle Scholar
• Zhang WY, Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol. 1998 Jul;105(7):780–789.
   PubMedGoogle Scholar
• Van Harselaar K. Chronic pelvic pain in women. Best Pract J. 2015 September;2015(70). https://bpac.org.nz/bpj/2015/september/pelvic.aspx
   Google Scholar
• Roberts E, Delgado Nunes V, Buckner S, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2016 Mar;75(3):552–559. doi: 10.1136/annrheumdis-2014-206914
   PubMed Web of Science ®Google Scholar
• Schroll JB, Black AY, Farquhar C, et al. Combined oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev. 2023 Jul 31 7(7):CD002120. doi: 10.1002/14651858.CD002120.pub4
   PubMedGoogle Scholar
• Chan WY, Dawood MY. Prostaglandin levels in menstrual fluid of nondysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive or ibuprofen therapy. Adv Prostaglandin Thromboxane Leukot Res. 1979;8:1443–1447.
   Google Scholar
• Jensen JT, Schlaff W, Gordon K. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertil Steril. 2018 Jul 1 110(1):137–152 e1. doi: 10.1016/j.fertnstert.2018.03.012
   PubMed Web of Science ®Google Scholar
• Brown J, Crawford TJ, Datta S, et al. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev. 2018 May 22 5(5):CD001019. doi: 10.1002/14651858.CD001019.pub3
   PubMedGoogle Scholar
• Bernardi M, Lazzeri L, Perelli F, et al. Dysmenorrhea and related disorders. F1000Res. 2017;6:1645.
   PubMedGoogle Scholar
• Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev. 2012 Mar 14 2012(3):CD002122. doi: 10.1002/14651858.CD002122.pub2
   PubMedGoogle Scholar
• Samy A, Taher A, Sileem SA, et al. Medical therapy options for endometriosis related pain, which is better? A systematic review and network meta-analysis of randomized controlled trials. J Gynecol Obstet Hum Reprod. 2021 Jan;50(1):101798. doi: 10.1016/j.jogoh.2020.101798
   PubMed Web of Science ®Google Scholar
• Edelman A, Micks E, Gallo MF, et al. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev. 2014 Jul 29 2014(7):CD004695. doi: 10.1002/14651858.CD004695.pub3
   PubMedGoogle Scholar
• Guideline F. FSRH guideline (January 2019) combined hormonal contraception (revision due by January 2024). BMJ Sex Reprod Health. 2019 Jan;45(Suppl 1):1–93.
   Google Scholar
• Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia. 2007 Mar;48(3):484–489. doi: 10.1111/j.1528-1167.2007.00997.x
   PubMed Web of Science ®Google Scholar
• Contin M, Albani F, Ambrosetto G, et al. Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy. Epilepsia. 2006 Sep;47(9):1573–1575. doi: 10.1111/j.1528-1167.2006.00558.x
   PubMed Web of Science ®Google Scholar
• King A, Bachman E, Macken MP, et al. Contraceptive vaginal ring reduces lamotrigine levels. Epilepsy Behav. 2020 Oct;111:107162.
   PubMed Web of Science ®Google Scholar
• Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia. 2005 Sep;46(9):1414–1417.
   PubMed Web of Science ®Google Scholar
• Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022(2):hoac009. doi: 10.1093/hropen/hoac009
   PubMedGoogle Scholar
• Veth VB, van de Kar MM, Duffy JM, et al. Gonadotropin-releasing hormone analogues for endometriosis. Cochrane Database Syst Rev. 2023 Jun 21 6(6):CD014788. doi: 10.1002/14651858.CD014788.pub2
   PubMedGoogle Scholar
• Whitaker LHR, Saraswat L, Horne AW. Combination GnRH antagonists for endometriosis: balancing efficacy with side effects.Cell Rep Med. 2022 Sep 20 3(9):100748. doi: 10.1016/j.xcrm.2022.100748
   PubMedGoogle Scholar
• Donnez J, Dolmans MM. Endometriosis and medical therapy: from progestogens to progesterone resistance to GnRH antagonists: a review.J Clin Med. 2021 Mar 5 10(5):1085. doi: 10.3390/jcm10051085
   PubMed Web of Science ®Google Scholar
• Ng J, Chwalisz K, Carter DC, et al. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017 May 1 102(5):1683–1691. doi: 10.1210/jc.2016-3845
   PubMed Web of Science ®Google Scholar
• Xin L, Ma Y, Ye M, et al. Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysis. Arch Gynecol Obstet. 2023 Oct;308(4):1047–1056. doi: 10.1007/s00404-022-06862-0
   PubMed Web of Science ®Google Scholar
• Ács N, O’Brien C, Jiang P, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist: results from a phase 2, randomized controlled study. J Endometr Pelvic Pain Disord. 2015;7(2):56–62. doi: 10.5301/je.5000211
   Web of Science ®Google Scholar
• Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017 Jul 6 377(1):28–40. doi: 10.1056/NEJMoa1700089
   PubMed Web of Science ®Google Scholar
• Giudice LC, As-Sanie S, Arjona Ferreira JC, et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet. 2022 Jun 18 399(10343):2267–2279. doi: 10.1016/S0140-6736(22)00622-5
   PubMed Web of Science ®Google Scholar
• D’Hooghe T, Fukaya T, Osuga Y, et al. Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study. Hum Reprod. 2019 May 1 34(5):813–823. doi: 10.1093/humrep/dez028
   PubMed Web of Science ®Google Scholar
• Donnez J, Taylor HS, Taylor RN, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020 Jul;114(1):44–55. doi: 10.1016/j.fertnstert.2020.02.114
   PubMed Web of Science ®Google Scholar
• Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012 Sep;98(3):511–519.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Gillott DJ, Venturini PL, et al. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol. 2011 Jun 21 9(1):89. doi: 10.1186/1477-7827-9-89
   PubMedGoogle Scholar
• Nave R, Mellinger U, Klein S, et al. Absence of drug-drug interaction of anastrozole on levonorgestrel delivered simultaneously by an intravaginal ring: results of a phase 2 trial. J Clin Pharmacol. 2019 Jul;59(7):1022–1028. doi: 10.1002/jcph.1396
   PubMed Web of Science ®Google Scholar
• Yu Q, Zhu X, Zhang X, et al. Etoricoxib in the treatment of primary dysmenorrhea in Chinese patients: a randomized controlled trial. Curr Med Res Opin. 2014 Sep;30(9):1863–1870. doi: 10.1185/03007995.2014.925437
   PubMed Web of Science ®Google Scholar
• Basri NI, Abd Ghani NA, Mahdy ZA, et al. Celecoxib versus mefenamic acid in the treatment of primary dysmenorrhea. Horm Mol Biol Clin Investig. 2020 Apr 17;41(3). doi: 10.1515/hmbci-2019-0069
   PubMed Web of Science ®Google Scholar
• Barra F, Scala C, Mais V, et al. Investigational drugs for the treatment of endometriosis, an update on recent developments. Expert Opin Investig Drugs. 2018 May;27(5):445–458. doi: 10.1080/13543784.2018.1471135
   PubMed Web of Science ®Google Scholar
• Machado DE, Berardo PT, Landgraf RG, et al. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis with an antiangiogenic effect in a rat model. Fertil Steril. 2010 May 15 93(8):2674–2679. doi: 10.1016/j.fertnstert.2009.11.037
   PubMed Web of Science ®Google Scholar
• Nenicu A, Gu Y, Korbel C, et al. Combination therapy with telmisartan and parecoxib induces regression of endometriotic lesions. Br J Pharmacol. 2017 Aug;174(16):2623–2635. doi: 10.1111/bph.13874
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Endocannabinoids and their pharmacological actions. Handb Exp Pharmacol. 2015;231:1–37.
   PubMedGoogle Scholar
• Sinclair J, Abbott J, Proudfoot A, et al. The place of cannabinoids in the treatment of gynecological pain. Drugs. 2023 Nov;83(17):1571–1579. doi: 10.1007/s40265-023-01951-z
   PubMed Web of Science ®Google Scholar
• Escudero-Lara A, Argerich J, Cabanero D, et al. Disease-modifying effects of natural Delta9-tetrahydrocannabinol in endometriosis-associated pain. Elife. 2020 Jan 14;9. doi: 10.7554/eLife.50356
   PubMed Web of Science ®Google Scholar
• Leconte M, Nicco C, Ngo C, et al. Antiproliferative effects of cannabinoid agonists on deep infiltrating endometriosis. Am J Pathol. 2010 Dec;177(6):2963–2970. doi: 10.2353/ajpath.2010.100375
   PubMed Web of Science ®Google Scholar
• Sanchez AM, Vigano P, Mugione A, et al. The molecular connections between the cannabinoid system and endometriosis. Mol Hum Reprod. 2012 Dec;18(12):563–571. doi: 10.1093/molehr/gas037
   PubMed Web of Science ®Google Scholar
• Urits I, Gress K, Charipova K, et al. Use of cannabidiol (CBD) for the treatment of chronic pain. Best Pract Res Clin Anaesthesiol. 2020 Sep;34(3):463–477. doi: 10.1016/j.bpa.2020.06.004
   PubMed Web of Science ®Google Scholar
• Turcotte C, Blanchet MR, Laviolette M, et al. The CB(2) receptor and its role as a regulator of inflammation. Cell Mol Life Sci. 2016 Dec;73(23):4449–4470. doi: 10.1007/s00018-016-2300-4
   PubMed Web of Science ®Google Scholar
• Bouaziz J, Bar On A, Seidman DS, et al. The clinical significance of endocannabinoids in endometriosis pain management. Cannabis Cannabinoid Res. 2017;2(1):72–80. doi: 10.1089/can.2016.0035
   PubMedGoogle Scholar
• Armour M, Sinclair J, Cheng J, et al. Endometriosis and cannabis consumption during the COVID-19 pandemic: an international cross-sectional survey. Cannabis Cannabinoid Res. 2022 Aug;7(4):473–481. doi: 10.1089/can.2021.0162
   PubMedGoogle Scholar
• Carrubba AR, Ebbert JO, Spaulding AC, et al. Use of cannabis for self-management of chronic pelvic pain. J Womens Health (Larchmt). 2021 Sep;30(9):1344–1351. doi: 10.1089/jwh.2020.8737
   PubMed Web of Science ®Google Scholar
• Busse JW, Vankrunkelsven P, Zeng L, et al. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ. 2021 Sep 8;374:n2040. doi: 10.1136/bmj.n2040
   PubMed Web of Science ®Google Scholar
• Mistry M, Simpson P, Morris E, et al. Cannabidiol for the management of endometriosis and chronic pelvic pain. J Minim Invasive Gynecol. 2022 Feb;29(2):169–176. doi: 10.1016/j.jmig.2021.11.017
   PubMed Web of Science ®Google Scholar
• Armour M, Parry K, Al-Dabbas MA, et al. Self-care strategies and sources of knowledge on menstruation in 12,526 young women with dysmenorrhea: a systematic review and meta-analysis. PLoS One. 2019;14(7):e0220103. doi: 10.1371/journal.pone.0220103
   PubMed Web of Science ®Google Scholar
• Wong CL, Ip WY, Lam LW. Self-care strategies among Chinese adolescent girls with dysmenorrhea: a qualitative study. Pain Manag Nurs. 2016 Aug;17(4):262–271.
   PubMed Web of Science ®Google Scholar
• Talebpour A, Mohammadifard M, Zare Feyzabadi R, et al. Effect of curcumin on inflammatory biomarkers and iron profile in patients with premenstrual syndrome and dysmenorrhea: a randomized controlled trial. Physiol Rep. 2023 Jul;11(13):e15763. doi: 10.14814/phy2.15763
   PubMed Web of Science ®Google Scholar
• Bahrami A, Zarban A, Rezapour H, et al. Effects of curcumin on menstrual pattern, premenstrual syndrome, and dysmenorrhea: a triple-blind, placebo-controlled clinical trial. Phytother Res. 2021 Dec;35(12):6954–6962. doi: 10.1002/ptr.7314
   PubMed Web of Science ®Google Scholar
• Jenabi E, Fereidooni B, Karami M, et al. The effect of bee prepolis on primary dysmenorrhea: a randomized clinical trial. Obstet Gynecol Sci. 2019 Sep;62(5):352–356. doi: 10.5468/ogs.2019.62.5.352
   PubMedGoogle Scholar
• Koblovska R, Mackova Z, Vitkova M, et al. Isoflavones in the Rutaceae family: twenty selected representatives of the genera Citrus, Fortunella, Poncirus, Ruta and Severinia. Phytochem Anal. 2008 Jan-Feb;19(1):64–70. doi: 10.1002/pca.1016
   PubMed Web of Science ®Google Scholar
• Tartaglia E, Armentano M, Giugliano B, et al. Effectiveness of the association n-palmitoylethanolamine and transpolydatin in the treatment of primary dysmenorrhea. J Pediatr Adolesc Gynecol. 2015 Dec;28(6):447–450. doi: 10.1016/j.jpag.2014.12.011
   PubMed Web of Science ®Google Scholar
• Stochino Loi E, Pontis A, Cofelice V, et al. Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: an open-label pilot study. Int J Womens Health. 2019;11:443–449.
   PubMed Web of Science ®Google Scholar
• Indraccolo U, Barbieri F. Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations. Eur J Obstet Gynecol Reprod Biol. 2010 May;150(1):76–79.
   PubMed Web of Science ®Google Scholar
• Beedie SL, Mahony C, Walker HM, et al. Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model. Sci Rep. 2016 Jul 22 6(1):30038. doi: 10.1038/srep30038
   PubMedGoogle Scholar
• Pellicer N, Galliano D, Herraiz S, et al. Use of dopamine agonists to target angiogenesis in women with endometriosis. Hum Reprod. 2021 Mar 18 36(4):850–858. doi: 10.1093/humrep/deaa337
   PubMed Web of Science ®Google Scholar
• DiVasta AD, Stamoulis C, Gallagher JS, et al. Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate. F S Rep. 2021 Dec;2(4):454–461. doi: 10.1016/j.xfre.2021.07.003
   PubMedGoogle Scholar
• Zhou D, Duan Z, Li Z, et al. The significance of glycolysis in tumor progression and its relationship with the tumor microenvironment. Front Pharmacol. 2022;13:1091779.
   PubMed Web of Science ®Google Scholar
• Young VJ, Ahmad SF, Duncan WC, et al. The role of TGF-beta in the pathophysiology of peritoneal endometriosis. Hum Reprod Update. 2017 Sep 1 23(5):548–559. doi: 10.1093/humupd/dmx016
   PubMed Web of Science ®Google Scholar
• Young VJ, Brown JK, Maybin J, et al. Transforming growth factor-beta induced Warburg-like metabolic reprogramming may underpin the development of peritoneal endometriosis. J Clin Endocrinol Metab. 2014 Sep;99(9):3450–3459. doi: 10.1210/jc.2014-1026
   PubMed Web of Science ®Google Scholar
• Horne AW, Ahmad SF, Carter R, et al. Repurposing dichloroacetate for the treatment of women with endometriosis. Proc Natl Acad Sci U S A. 2019 Dec 17 116(51):25389–25391. doi: 10.1073/pnas.1916144116
   PubMed Web of Science ®Google Scholar
• Leow HW, Koscielniak M, Williams L, et al. Dichloroacetate as a possible treatment for endometriosis-associated pain: a single-arm open-label exploratory clinical trial (EPiC). Pilot Feasibility Stud. 2021 Mar 12 7(1):67. doi: 10.1186/s40814-021-00797-0
   PubMedGoogle Scholar
• Hawkey A, Chalmers KJ, Micheal S, et al. “A day-to-day struggle”: a comparative qualitative study on experiences of women with endometriosis and chronic pelvic pain. Fem Psychol. 2022;32(4):482–500. doi: 10.1177/09593535221083846
   Web of Science ®Google Scholar
• Sinaii N, Cleary SD, Younes N, et al. Treatment utilization for endometriosis symptoms: a cross-sectional survey study of lifetime experience. Fertil Steril. 2007 Jun;87(6):1277–1286. doi: 10.1016/j.fertnstert.2006.11.051
   PubMed Web of Science ®Google Scholar
• Evans S, Villegas V, Dowding C, et al. Treatment use and satisfaction in Australian women with endometriosis: a mixed-methods study. Intern Med J. 2022 Dec;52(12):2096–2106. doi: 10.1111/imj.15494
   PubMed Web of Science ®Google Scholar
• Jain V, Chodankar RR, Maybin JA, et al. Uterine bleeding: how understanding endometrial physiology underpins menstrual health. Nat Rev Endocrinol. 2022 May;18(5):290–308. doi: 10.1038/s41574-021-00629-4
   PubMed Web of Science ®Google Scholar
• Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update. 2015 Nov-Dec;21(6):762–778.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. WHO global report on traditional and complementary medicine. Geneva: World Health Organisation; 2019.
   Google Scholar
• Abubakar U, Zulkarnain AI, Samri F, et al. Use of complementary and alternative therapies for the treatment of dysmenorrhea among undergraduate pharmacy students in Malaysia: a cross sectional study. BMC Compl Med Ther. 2020 Sep 18 20(1):285. doi: 10.1186/s12906-020-03082-4
   PubMedGoogle Scholar
• Samba Conney C, Akwo Kretchy I, Asiedu-Danso M, et al. Complementary and alternative medicine use for primary dysmenorrhea among senior high school students in the Western Region of Ghana. Obstet Gynecol Int. 2019;2019:8059471.
   PubMed Web of Science ®Google Scholar
• Munstedt K, Riepen T. Patients’ decisions regarding the treatment of primary dysmenorrhoea. Complement Ther Med. 2019 Aug;45:1–6.
   PubMed Web of Science ®Google Scholar
• Stohs SJ, Chen O, Ray SD, et al. Highly bioavailable forms of curcumin and promising avenues for curcumin-based research and application: a review. Molecules. 2020 Mar 19 25(6):1397. doi: 10.3390/molecules25061397
   PubMed Web of Science ®Google Scholar
• Chayasirisobhon S. Mechanisms of action and pharmacokinetics of cannabis. Perm J. 2020 Dec;25:1–3.
   Google Scholar
• O’Hara R, Rowe H, Fisher J. Managing endometriosis: a cross-sectional survey of women in Australia [Article]. J Psychosom Obstet Gynaecol. 2022 Sep;43(3):265–272.
   PubMed Web of Science ®Google Scholar
• French L. Dysmenorrhea in adolescents: diagnosis and treatment. Paediatr Drugs. 2008;10(1):1–7.
   PubMedGoogle Scholar
• Armour M, Dahlen HG, Smith CA. More than needles: the importance of explanations and self-care advice in treating primary dysmenorrhea with acupuncture. Evid Based Complement Alternat Med. 2016;2016:1–11.
   Web of Science ®Google Scholar
• Yesuf TA, Eshete NA, Sisay EA. Dysmenorrhea among university health science students, northern Ethiopia: impact and associated factors. Int J Reprod Med. 2018;2018:9730328.
   PubMedGoogle Scholar
• Chiou MH, Wang HH. Predictors of dysmenorrhea and self-care behavior among vocational nursing school female students. J Nurs Res: JNR. 2008 Mar;16(1):17–25.
   Google Scholar
• Wong LP. Attitudes towards dysmenorrhoea, impact and treatment seeking among adolescent girls: a rural school-based survey. Aust J Rural Health. 2011 Aug;19(4):218–223.
   PubMed Web of Science ®Google Scholar
• Wijesiri HS, Suresh TS. Knowledge and attitudes towards dysmenorrhea among adolescent girls in an urban school in Sri Lanka. Nurs Health Sci. 2013 Mar;15(1):58–64.
   PubMed Web of Science ®Google Scholar
• Devi UT. A study on coping strategies of menstrual disturbances among adolescent girls at selected schools of Coimbatore District. Asian J Nurs Educ Res. 2014;4(2):220–223.
   Google Scholar
• Armour M, Smith CA, Steel KA, et al. The effectiveness of self-care and lifestyle interventions in primary dysmenorrhea: a systematic review and meta-analysis [journal article]. BMC Complement Altern Med. 2019 Jan 17 19(1):22. doi: 10.1186/s12906-019-2433-8
   PubMedGoogle Scholar
• Ni Cheileachair F, McGuire BE, Durand H. Coping with dysmenorrhea: a qualitative analysis of period pain management among students who menstruate.BMC Womens Health. 2022 Oct 5 22(1):407. doi: 10.1186/s12905-022-01988-4
   PubMed Web of Science ®Google Scholar